Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress
TheFly reported on June 3 that UBS increased its price target on LEGN to $49 from $31 while reiterating a Buy rating on the stock.
Legend Biotech Corp (LEGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 7,687,638 | $139,069,371 | +30% | 1.64% |
| 2. | Suvretta Capital Management Aaron Cowen | 7,581,029 | $137,140,815 | +15% | 3.5% |
| 3. | Hillhouse Capital Management Lei Zhang | 5,984,550 | $108,260,510 | 6.47% | |
| 4. | Point72 Asset Management Steve Cohen | 3,886,017 | $70,298,048 | +40% | 0.09% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,890,396 | $34,197,264 | +175% | 0.03% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.80 | 6,000 | $88,800.00 | 48,604 | 2026-06-30 | Filing | |
| $14.78 | 5,566 | $82,265.48 | 241,872 | 2026-06-25 | Filing | |
| $8.77 | 9,936 | $87,138.72 | 247,438 | 2026-03-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,915,056 | $55,306,817 | 0.07% | |
| 2. | 8,133 | $234,881 | 0.01% | |
| 3. | 616 | $17,790 | 0% | |
| 4. | 48 | $1,387 | 0% | |
| 5. | 41,500 | $1,199 | 0% |
News See All
10 Best Healthcare Stocks to Buy According to Wall Street Analysts
The U.S. healthcare sector has significantly lagged the broader market for three consecutive years, returning just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
10 Most Promising Healthcare Stocks According to Wall Street Analysts
The US healthcare sector has trailed the broader market for three consecutive years, returning just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
Legend Biotech (LEGN) Soars 42% on Promising Cancer Therapy Results
Legend Biotech snapped a four-day losing streak on Tuesday, jumping 42.22 percent to close at $36.28 apiece following the strong first phase results of its cancer treatment candidate, which saw as much...
10 Stocks Delivering Massive Returns
Ten stocks soared by double-digits on Tuesday, with seven notably notching new record highs, as investors took heart from a flurry of developments, including strong earnings and optimistic outlooks, among...
10 Under-the-Radar Stocks with Massive Upside for 2026
The benchmark 10-year Treasury yield hit its highest level since January 2025 that same week, while the 30-year yield briefly touched its highest since 2007, Reuters reported.
Legend Biotech Corporation (NASDAQ:LEGN) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Legend Biotech First Quarter 2026 Earnings Conference Call. [Operator Instructions] Today's conference is being recorded.
10 Stocks With Stunning Gains
Ten stocks boasted strong gains on Tuesday, outperforming a lackluster performance on Wall Street, as investors continued to digest a flurry of strong corporate earnings.
10 Best Biotech Stocks with Highest Upside Potential
On April 16, reports from J.P. Morgan's biopharma and medtech venture and licensing studies indicated that the capital markets began the year 2026 with selective strength.
10 Stocks With Double-Digit Returns
Ten stocks kicked off the trading week with double-digit gains, defying a lackluster performance on the broader market, as investors turned to positive developments to bolster their buying appetite.
Hedge Fund Resource Center